Selected JAKi trials in ET
| Agent . | Target(s) . | Clinical trial . | Numerosity and study-specific features . | Key results . | Toxicities . | Comments . |
|---|---|---|---|---|---|---|
| RUX | JAK1/2 | MAJIC-ET,100 RUX vs BAT | RUX (n = 58), BAT (n = 52); HU resistant/ intolerant | Complete response rate within 1 y: RUX (46.6%) vs BAT (44.2%); at 2 y, rates of thrombosis, hemorrhage, and transformation were not significantly different | G3/4 anemia, 21% RUX vs 0% BAT (2 patients discontinued RUX for anemia); G3/4 thrombocytopenia, 3.4% RUX vs 0% BAT; infections, 15.5% G3 RUX vs 3.5% G3/4 BAT | RUX is not superior to current second-line treatments for ET |
| Agent . | Target(s) . | Clinical trial . | Numerosity and study-specific features . | Key results . | Toxicities . | Comments . |
|---|---|---|---|---|---|---|
| RUX | JAK1/2 | MAJIC-ET,100 RUX vs BAT | RUX (n = 58), BAT (n = 52); HU resistant/ intolerant | Complete response rate within 1 y: RUX (46.6%) vs BAT (44.2%); at 2 y, rates of thrombosis, hemorrhage, and transformation were not significantly different | G3/4 anemia, 21% RUX vs 0% BAT (2 patients discontinued RUX for anemia); G3/4 thrombocytopenia, 3.4% RUX vs 0% BAT; infections, 15.5% G3 RUX vs 3.5% G3/4 BAT | RUX is not superior to current second-line treatments for ET |